27 results on '"L. Barkoff"'
Search Results
2. A Single Center Look at Pediatric Heart Re-Transplantation
- Author
-
K. Wujcik, L. Barkoff, D. Lee, E.L. Profita, C. Chen, and S.A. Hollander
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
3. Impact of the 2018 Adult Heart Allocation Change on Pediatric Donor Offers and Waitlist Outcomes
- Author
-
K.R. Sweat, B. Kaufman, L. Barkoff, C. Chen, E. Profita, E. Lee, M. Rosenberg, S. Chen, S. Hollander, and C. Almond
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
4. The End-of-Life Experience of Pediatric Heart Transplant Recipients
- Author
-
John C. Dykes, L. Barkoff, Daniel Bernstein, Seth A. Hollander, Beth D. Kaufman, Harvey J. Cohen, Sharon Chen, Barbara Sourkes, and David N. Rosenthal
- Subjects
Male ,Resuscitation ,Pediatrics ,medicine.medical_specialty ,Palliative care ,Context (language use) ,030204 cardiovascular system & hematology ,California ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,law ,Prevalence ,Humans ,Medicine ,030212 general & internal medicine ,Child ,General Nursing ,Retrospective Studies ,Heart Failure ,Terminal Care ,business.industry ,Palliative Care ,Do not resuscitate ,Infant ,Emergency department ,Intensive care unit ,Hospitalization ,Survival Rate ,Transplantation ,Intensive Care Units ,Anesthesiology and Pain Medicine ,Child, Preschool ,Cohort ,Heart Transplantation ,Female ,Neurology (clinical) ,business - Abstract
Context Despite advances in therapies, many pediatric heart transplant (Htx) recipients will die prematurely. We characterized the circumstances surrounding death in this cohort, including location of death and interventions performed in the final 24 hours. Methods We reviewed all patients who underwent Htx at Lucile Packard Children's Hospital, Stanford, survived hospital discharge, and subsequently died between July 19, 2007 and September 13, 2015. The primary outcome studied was location of death, characterized as inpatient, outpatient, or emergency department. Circumstances of death (withdrawal of life-sustaining treatment, death during resuscitation, or death without resuscitation with/without do not resuscitate) and interventions performed in the last 24 hours of life were also analyzed. Results Twenty-three patients met the entry criteria. The median age at death was 12 (range 2–20) years, and the median time between transplant and death was 2.8 (range 0.8–11) years. Four (17%) died at home, and three (13%) died in the emergency department. Sixteen (70%) patients died in the hospital, 14 of 16 (88%) of whom died in an intensive care unit. Five of 23 (22%) patients experienced attempted resuscitation. Interventions performed in the last 24 hours of life included intubation (74%), mechanical support (30%), and dialysis (22%). Most patients had a recent outpatient clinical encounter with normal graft function within 60 days of dying. Conclusions/Lessons Learned Death in children after Htx often occurs in the inpatient setting, particularly the intensive care unit. Medical interventions, including attempted resuscitation, are common at the end of life. Given the difficulty in anticipating life-threatening events, earlier discussions with patients regarding end-of-life wishes are appropriate, even in those with normal graft function.
- Published
- 2017
- Full Text
- View/download PDF
5. The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial
- Author
-
Seth A. Hollander, Kevin P. Daly, Joseph W. Rossano, Matthew Fenton, J. Lee, Ashwin K. Lal, M.J. Bock, Christopher S. Almond, Gloria L. Klein, Elfriede Pahl, L. Barkoff, Lynn A. Sleeper, and Chesney Castleberry
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,Everolimus ,business.industry ,Trial study ,Fda approval ,030230 surgery ,Coronary disease ,Tacrolimus ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,Surgery ,Pediatric heart transplantation ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Rare disease - Abstract
Purpose Currently there are no-FDA approved immunosuppressants specific to pediatric heart transplantation (HT). In recent years, everolimus (EVL) has emerged as an alternative to tacrolimus (TAC) as a primary immunosuppressant to prevent rejection that may also prevent kidney and coronary disease. However, the two regimens have never been evaluated systematically. Methods The TEAMMATE Trial (IND 127980) is designed to evaluate the safety and efficacy of EVL and low-dose (LD-TAC) compared to standard-therapy TAC and mycophenolate mofetil (MMF). The study design and rationale are reviewed in light of challenges inherent in rare disease research. Results The TEAMMATE trial is the first multicenter randomized clinical trial (RCT) in pediatric HT. The primary purpose is to evaluate the risk-benefit profile of the two regimens to prevent major adverse transplant events (MATE), and to support FDA approval of 1 or both regimens for pediatric HT. Children Conclusion The TEAMMATE trial is the first RCT in pediatric HT. It is anticipated that the study will provide important information about the safety and effectiveness of EVL and TAC and provide valuable lessons into the design and conduct of future trials in pediatric HT.
- Published
- 2020
- Full Text
- View/download PDF
6. Heightened Immune Response and Increased Risk of Infections in Pediatric Fontan Patients after Heart Transplantation
- Author
-
Seth A. Hollander, John C. Dykes, Beth D. Kaufman, E. Profita, Donna C. Lee, L. Barkoff, J. Lee, Shuping Chen, Daniel Bernstein, H. Ahmed, and David N. Rosenthal
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,Retrospective cohort study ,Dilated cardiomyopathy ,medicine.disease ,Gastroenterology ,Post-transplant lymphoproliferative disorder ,Thymectomy ,Internal medicine ,medicine ,Clinical endpoint ,Surgery ,Respiratory system ,Cardiology and Cardiovascular Medicine ,business - Abstract
Purpose Infectious complications are a major cause of morbidity & mortality after heart transplantation (HT). Patients who have undergone Fontan palliation may have a higher susceptibility to post HT infections given thymectomy in infancy and known depletions of T-cell subsets. Methods This was a single-center, retrospective cohort analysis of pediatric patients undergoing HT for dilated cardiomyopathy (DCM) or failing Fontan physiology, who underwent post HT induction with anti-thymoglobulin (ATG). Repeat HTs and multi organ transplants were excluded. The primary endpoint was infection in the first 180 days post HT, defined as 1) positive blood, urine, or respiratory culture; 2) positive viral PCR (excluding CMV and EBV); 3) skin or wound infection; or 4) culture-negative infection if a full antibiotic course (≥ 5 days) was completed. Secondary endpoints included sensitivity to ATG as defined by 1) absolute lymphocyte (ALC) and CD3 counts after 5 doses; 2) the incidence of post transplant lymphoproliferative disorder (PTLD); and 3) rejection (>/= Grade 2R ACR or pAMR2) in the first 180 days post HT. Results From 1/2014 to 9/2019, 63 patients (30 Fontan, 33 DCM) underwent HT at a median of 15.4 (IQR 10.8, 20.1) and 11.7 (IQR 1.4, 13.6) years, respectively. The median total ATG received was 7.5 (IQR 6.7, 8.2) mg/kg vs 7.2 (IQR 4.7, 9.2) mg/kg (p=NS), respectively. The median CD3 [9 (IQR 3,14) vs 12 (IQR 6, 26); p=0.04, Figure 1A] and lymphocyte counts [172 (IQR 98, 354) vs 427 (IQR 205, 662); p=0.02] after ATG were lower in Fontan vs DCM patients. 28 patients (41%) developed at least one infection within 180 days after HT, with a higher rate of infection in Fontan patients (60% vs 24%, p=0.005; Figure 1B). There was no difference in the incidence of PTLD (10% vs 0%; p=0.1) or rejection (17% vs 27%; p=0.31) between Fontan vs DCM patients, respectively. Conclusion Compared to DCM patients, Fontan patients have a more pronounced suppression of CD3 counts after induction, as well as a higher risk of infection.
- Published
- 2020
- Full Text
- View/download PDF
7. Healthy Hearts via Live Videoconferencing: An Exercise and Diet Intervention in Pediatric Heart Transplant Recipients
- Author
-
Jerrid Brabender, L. Barkoff, Angela C. Chen, Katie Jo Stauffer, Faustine D. Ramirez, Jeffrey Kazmucha, S. Stillman Berry, David N. Rosenthal, Donna C. Lee, C. Jason Wang, Susan E. Nourse, Inger Olson, Nancy McDonald, Elif Seda Selamet Tierney, and Sarah C. Couch
- Subjects
Male ,Percentile ,Time Factors ,Saturated fat ,medicine.medical_treatment ,Health Status ,030204 cardiovascular system & hematology ,Pediatrics ,0302 clinical medicine ,endothelial function ,Interquartile range ,Pediatric Cardiology ,030212 general & internal medicine ,Child ,Original Research ,Diet and Nutrition ,Heart transplantation ,education.field_of_study ,Age Factors ,VO2 max ,Treatment Outcome ,Female ,Diet, Healthy ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Adolescent ,Population ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Humans ,education ,Exercise ,heart transplant ,Telerehabilitation ,Heart Failure ,Transplantation ,business.industry ,Recovery of Function ,Clinical trial ,Videoconferencing ,Feasibility Studies ,Heart Transplantation ,Patient Compliance ,live videoconferencing ,business ,Exercise Testing ,Body mass index ,Risk Reduction Behavior - Abstract
Background Pediatric heart transplant recipients have high‐risk cardiovascular profiles that can affect their long‐term outcomes; however, promoting exercise and healthy diet has not been a major focus in the field. The objective of this study was to test the feasibility and impact of a supervised exercise and diet intervention delivered via live videoconferencing in this population. Methods and Results Patients 8 to 19 years of age at least 1 year post heart transplantation were enrolled. The 12‐ to 16‐week intervention phase included live video–supervised exercise (×3/week) and nutrition (×1/week) sessions. The 12‐ to 16‐week maintenance phase included ×1/week live video–supervised exercise and nutrition sessions and ×2/week self‐directed exercise sessions. Cardiac, vascular, nutritional, and functional health indices were obtained at baseline, after intervention, and after maintenance. Fourteen patients (median age, 15.2; interquartile range, 14.3–16.7 years) at a median of 3.3 (interquartile range, 1.5–9.7) years after heart transplant completed the intervention. Patients attended 89.6±11% of exercise and 88.4±10% of nutrition sessions during the intervention and 93.4±11% of exercise and 92.3±11% of nutrition sessions during maintenance. After intervention, body mass index percentile (median, −27%; P =0.02), endothelial function (median, +0.29; P =0.04), maximum oxygen consumption (median, +2 mL/kg per minute; P =0.002). Functional Movement Screening total score (median, +2.5; P =0.002) and daily consumption of saturated fat (median, −6 g; P =0.02) improved significantly. After maintenance, improvements in maximum oxygen consumption (median, +3.2 mL/kg per minute; P =0.02) and Functional Movement Screening total score (median, +5; P =0.002) were sustained. Conclusions In pediatric heart transplant recipients, a live video–supervised exercise and diet intervention is feasible. Our results demonstrate excellent adherence with significant improvements in cardiovascular and functional health. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02519946.
- Published
- 2020
8. Pediatric waitlist and heart transplant outcomes in patients with syndromic anomalies
- Author
-
David N. Rosenthal, Seth A. Hollander, L. Barkoff, Sarah J. Wilkens, Beth D. Kaufman, and James R. Priest
- Subjects
Male ,medicine.medical_specialty ,Mitochondrial Diseases ,Adolescent ,Waiting Lists ,medicine.medical_treatment ,030232 urology & nephrology ,Length of hospitalization ,Chromosome Disorders ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Hospital discharge ,Prevalence ,Intubation ,Humans ,In patient ,Child ,Connective Tissue Diseases ,Retrospective Studies ,Heart Failure ,Transplantation ,Retrospective review ,business.industry ,Infant, Newborn ,Infant ,Syndrome ,Survival Analysis ,Case-Control Studies ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Heart Transplantation ,Female ,Waitlist mortality ,business - Abstract
Purpose We sought to determine whether the presence of a systemic SA with potential complicating factors affects waitlist and post-HT outcomes in pediatric patients. Methods This is a single-center retrospective review of pediatric patients listed for HT between January 1, 2009, and July 1, 2018. Patients were selected based on the presence of any underlying syndromes, which included chromosomal anomalies, skeletal myopathies, connective tissue disorders, mitochondrial disease,and other systemic disorders. Waitlist and post-HT outcomes were compared to those without SA. Results A total of 243 patients were listed for HT, of which 21 (9%) patients had associated SA. Of those, 16 (76%) survived to transplant, 3 (14%) died while on the waitlist, 1 (5%) improved and was removed from the waitlist, and 1 (5%) patient is currently listed. Waitlist survival was not different between those with/without an associated syndrome (P = 1.0). Among those who survived to HT, there was no difference in listing days (70 vs 90, P = .8), survival to hospital discharge [14 (93%) vs 150 (95%), P = .6], post-HT intubation days (2 vs 2 days, P = .6), or post-HT hospital length of stay (18 vs 18 days, P = .8). Overall survival during the study period post-HT was not different between groups (P = .8). Conclusion A SA was present in 9% of pediatric patients wait-listed for HT, but was not associated with an increased waitlist mortality or post-HT hospital morbidity or long-term survival. For several anomalies, HT is safe and feasible.
- Published
- 2019
9. Induction and Increased Risk of Infections in Pediatric Fontan Patients after Heart Transplantation
- Author
-
J. Lee, David N. Rosenthal, L. Barkoff, Kenneth I. Weinberg, Shuping Chen, Seth A. Hollander, Daniel Bernstein, H. Ahmed, and Donna C. Lee
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,Retrospective cohort study ,Dilated cardiomyopathy ,Urine ,medicine.disease ,Gastroenterology ,Thymectomy ,Internal medicine ,medicine ,Clinical endpoint ,Surgery ,Respiratory system ,Cardiology and Cardiovascular Medicine ,business - Abstract
Purpose To understand whether patients who have undergone Fontan palliation may have a higher susceptibility to post-HT infections given thymectomy in infancy and known depletions of T-cell subsets. Methods This was a single-center, retrospective cohort analysis of pediatric patients undergoing HT for dilated cardiomyopathy (DCM) or Fontan failure, who underwent induction with anti-thymoglobulin (ATG). The primary endpoint was infection in the first 180 days post-HT, defined as (1) positive blood/urine/respiratory culture; (2) positive viral PCR (excluding CMV and EBV); (3) skin or wound infection; and/or (4) culture-negative infection if a full antibiotic course (>5 days) was completed. Secondary endpoints included (1) absolute lymphocyte (ALC) and CD3 counts after 3 and 5 doses of anti-thymocyte gammaglobulin (ATG); (2) the incidence of post-transplant lymphoproliferative disorder (PTLD); and (3) rejection (≥ Grade 2R ACR or pAMR2) in the first 180 days post-HT. Results From 2014 to 2019, 59 pts (26 Fontan, 33 DCM) underwent HT at a median age of 14.7 (IQR 10.6, 19.5) and 11.7 (IQR 1.4, 13.6) years, respectively. The median total ATG received was 7.4 (IQR 4.9, 7.7) vs 7.5 (IQR 7.3, 7.6) mg/kg (p=NS). The median CD3 [8 (IQR 5, 14) vs 16 (IQR 10, 39); p=0.01] after 3 doses of ATG and ALC [172 (IQR 98, 400) vs 427 (IQR 205, 824); p=0.014] after 5 doses of ATG was lower in Fontan vs DCM patients (A,B). Twenty-three patients (39%) developed ≥1 infection within 180 days post-HT, with a higher rate of infection in Fontan patients (54% vs 27%, p=0.03; C, D). Adjusted for pre-transplant ALC, the risk for infection within 30 days post-HT for Fontan patients was OR 7.62, 95% CI 1.13-51.48, p=0.037. There was no difference in the incidence of PTLD (12% vs 0%; p=0.08) or rejection (12% vs 21%; p=0.49) between Fontan vs DCM patients. Conclusion Compared to DCM patients, Fontan patients have lower CD3 and ALC after induction, as well as a higher risk of infection. Modifications to induction therapy for Fontan patients may be considered.
- Published
- 2021
- Full Text
- View/download PDF
10. Taking a Closer Look at Distance: Does Increasing the Maximal Donor Distance Range Shorten Waitlist Times in Pediatric Heart Transplant Candidates?
- Author
-
E. Profita, Christopher S. Almond, John C. Dykes, Seth A. Hollander, K. Wujcik, L. Barkoff, David N. Rosenthal, Katsuhide Maeda, and Beth D. Kaufman
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,business.industry ,Range (statistics) ,Medicine ,Ischemic time ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Weight range ,Linear distance ,Demography ,Patient factors - Abstract
Purpose Data suggest that pediatric heart transplant (HT) centers can reduce waitlist time by expanding donor catchment vis expanded parameters including the maximal donor weight range. Contrary to donor weight ranges, little is known about the effect of increasing the donor distance (DD) range. We sought to determine whether increasing the DD range can reduce waitlist time and how well actual DD predicts ischemic time (IT). Methods All US children Results Among 4,240 children who met study criteria, the median age was 2 (IQR 0, 11) years, weight 12 (6, 35) kg, 53% had CHD. Centers varied considerably in their maximal DD range (1000-10,000 miles); median 1500 miles (Figure A). Overall, 86% of donors originated from ≤500 miles; 97% ≤1,000 miles (Figures A & B) with sharp drop-offs at 500 and 1000 miles (Figure B). After adjusting for patient factors, maximal DD range was associated with a shorter waitlist time. The correlation between actual DD and IT is fair (R=0.69) but explains only half (R2=0.49) of the variability in IT. Conclusion Pediatric HT centers vary considerably in their maximal donor distance ranges, though most donors still fall within 500-1000 miles of recipients. Increasing the maximal DD range appears is associated with a shorter waitlist time. Actual DD explains only half of the variability in IT. Further research is needed to understand the optimal regional sharing distance for organ allocation and whether contemporary navigational software could better predict IT than the linear distance to the donor hospital.
- Published
- 2020
- Full Text
- View/download PDF
11. The Use of Patient-Reported Outcomes to Screen for Underrecognized Psychiatric Co-Morbidities in Adolescent and Young Adult Cardiac Transplant Recipients
- Author
-
L. Bennett Murphy, Lauren M. Schneider, Daniel Cox, J. Stehlik, Nancy McDonald, Sharon Chen, Lindsay J. May, L. Barkoff, A. Hoskoppal, and Tyler Brown
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,education.field_of_study ,medicine.medical_specialty ,Heart disease ,business.industry ,Population ,medicine.disease ,Exact test ,McNemar's test ,medicine ,Anxiety ,Surgery ,Young adult ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Prospective cohort study ,education ,Psychiatry ,business ,Depression (differential diagnoses) - Abstract
Purpose For adolescents and young adults, receiving a heart transplant is a profoundly challenging experience. This pilot study examined the burden of psychiatric co-morbidities and resiliency factors in post-transplant patients using patient-reported outcomes (PRO). Methods Patients transplanted between ages 15-25 years at one of three tertiary care centers were asked to complete six PRO measures—PROMIS® measures to assess depression, anxiety, satisfaction with social roles (SSR), and physical functioning (PF); Posttraumatic Stress Diagnostic Scale for DSM-5 (PDS-5) for Posttraumatic Stress Disorder (PTSD); and the Connor-Davidson Resilience Scale-10 for resiliency. Formal psychiatric diagnoses and demographics were collected retrospectively from chart review. Comparisons were made between PRO measures and formal diagnoses, with further comparison between those transplanted for congenital heart disease (CHD) and cardiomyopathy (CM). PROMIS® scores were dichotomized at their literature-reported cutoffs for depression and anxiety. Fisher's exact test, McNemar's test for paired samples, and Wilcoxon rank-sum test were used as appropriate. Results We enrolled 14 patients (median age at transplant 17.9 years [IQR 16.5, 20.7 yr]; 86% male and 64% with CM). Of 13 with complete data, 8/13 patients (62%) had at least mild PTSD symptoms and 3/13 (23%) had PDS-5 scores indicating probable PTSD diagnosis. Only one patient carried a formal diagnosis of PTSD. 5/13 (39%) patients had probable depression by PROMIS®. Compared to CM patients, CHD patients had more severe PTSD symptoms (p = 0.035), higher depression scores (p = 0.018) and lower PF and SSR PROMIS® scores (p = 0.017 and 0.003, respectively). Conversely, CM patients had higher resiliency scores (p = 0.021). Conclusion In this pilot study, we found high prevalence of PTSD and depression symptoms with discordant formal psychiatric diagnoses. This suggests that these disorders may be underrecognized in the adolescent and young adult heart transplant population. The routine use of PRO measures should be tested in an expanded prospective study to further evaluate their screening utility for psychiatric co-morbidities among members of this vulnerable population.
- Published
- 2019
- Full Text
- View/download PDF
12. Healthy hearts in pediatric heart transplant patients with an exercise and diet intervention via live video conferencing-Design and rationale
- Author
-
Inger Olson, L. Barkoff, Katie Jo Stauffer, Elif Seda Selamet Tierney, Donna C. Lee, S. Stillman Berry, Jerrid Brabender, C. Jason Wang, Susan E. Nourse, Nancy McDonald, Angela C. Chen, Jeffrey Kazmucha, David N. Rosenthal, and Sarah C. Couch
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Saturated fat ,Health Behavior ,030232 urology & nephrology ,Health Promotion ,030230 surgery ,Young Adult ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Quality of life ,Internal medicine ,Intervention (counseling) ,medicine ,Humans ,Healthy Lifestyle ,Child ,Reactive hyperemia ,Pulse wave velocity ,Transplantation ,business.industry ,VO2 max ,medicine.disease ,Telemedicine ,Exercise Therapy ,Transplant rejection ,Treatment Outcome ,Cardiovascular Diseases ,Research Design ,Pediatrics, Perinatology and Child Health ,Videoconferencing ,Feasibility Studies ,Heart Transplantation ,Patient Compliance ,Female ,business ,Diet Therapy - Abstract
BACKGROUND Pediatric heart transplant (PedHtx) patients have increased cardiovascular risk profiles that affect their long-term outcomes and quality of life. We designed a 12- to 16-week diet and exercise intervention delivered via live video conferencing to improve cardiovascular health. Our methodology and baseline assessment of the first 13 enrolled patients are reported. METHODS Inclusion criteria are as follows: (a) 8-19 years old; (b) heart transplant >12 months; (c) ability to fast overnight; (d) cardiac clearance by cardiologist; and (e) presence of an adult at home during exercise sessions for patients
- Published
- 2018
- Full Text
- View/download PDF
13. Center Variation in Listing Parameters Among US Pediatric Heart Transplant Programs
- Author
-
S. Chen, Yingze Zhang, L. Barkoff, Christopher S. Almond, John C. Dykes, K. Maeda, Nancy McDonald, Seth A. Hollander, David N. Rosenthal, and S.J. Wilkens
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,business.industry ,Listing (computer) ,030204 cardiovascular system & hematology ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,Variation (linguistics) ,Family medicine ,medicine ,Surgery ,Center (algebra and category theory) ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
14. Poverty Is an Independent Socioeconomic Risk Factor for Death Following Pediatric Heart Transplant
- Author
-
L. Barkoff, David M. Peng, Seth A. Hollander, John C. Dykes, Daniel Bernstein, Beth D. Kaufman, David N. Rosenthal, and Christopher S. Almond
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,Poverty ,business.industry ,Medicine ,Surgery ,Risk factor ,Cardiology and Cardiovascular Medicine ,business ,Intensive care medicine ,Socioeconomic status - Published
- 2016
- Full Text
- View/download PDF
15. The End-of-Life Experience in Pediatric Heart Transplant Recipients
- Author
-
John C. Dykes, Daniel Bernstein, Sharon Chen, Seth A. Hollander, Beth D. Kaufman, David N. Rosenthal, and L. Barkoff
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine ,Surgery ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business - Published
- 2016
- Full Text
- View/download PDF
16. Impact of the 18th Birthday on Wait-list Outcome for US Patients Listed for Heart Transplant
- Author
-
Christopher S. Almond, Seth A. Hollander, A. Lin, David N. Rosenthal, Olaf Reinhartz, L. Barkoff, J. Yeh, David M. Peng, and Nancy McDonald
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,business.industry ,General surgery ,medicine ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Outcome (game theory) - Published
- 2015
- Full Text
- View/download PDF
17. Does the OPTN cPRA Calculator Accurately Predict HLA Antigen Frequencies in Pediatric Donors?
- Author
-
Dolly B. Tyan, Seth A. Hollander, Sharon Chen, Beth D. Kaufman, L. Barkoff, Christopher S. Almond, Daniel Bernstein, M.A. Fernandez-Vina, Katsuhide Maeda, and David N. Rosenthal
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,Ejection fraction ,business.industry ,medicine.medical_treatment ,Diastole ,Human leukocyte antigen ,Postcapillary pulmonary hypertension ,Internal medicine ,medicine ,Cardiology ,Lung transplantation ,Surgery ,Risk factor ,Cardiology and Cardiovascular Medicine ,business - Abstract
s S161 Survival after lung transplantation did not differ significantly for patients with pPH, pcPH and Non-PH, and no difference in survival was observed between patients with IpcPH and CpcPH (log-rank P= 0.913). Conclusion: Postcapillary pulmonary hypertension occurred in 11.1% of patients, and was not verified as a risk factor for post-transplant survival whether of isolated or combined type. Patients with diastolic dysfunction and preserved systolic ejection fraction should not be excluded from lung transplantation.
- Published
- 2015
- Full Text
- View/download PDF
18. United Stated Trends in Pediatric Heart Transplantation: Are We Busier or Does It Just Feel That Way?
- Author
-
Katsuhide Maeda, Esther Liu, L. Mikula Schneider, David N. Rosenthal, Lan N. Doan, Christopher S. Almond, Beth D. Kaufman, Mary Burge, Nancy McDonald, K. Jensen, Daniel Bernstein, and L. Barkoff
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine ,Surgery ,Pediatric heart transplantation ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business - Published
- 2015
- Full Text
- View/download PDF
19. Contemporary Pediatric Heart Transplant Waitlist Mortality.
- Author
-
Power A, Sweat KR, Roth A, Dykes JC, Kaufman B, Ma M, Chen S, Hollander SA, Profita E, Rosenthal DN, Barkoff L, Chen CY, Davies RR, and Almond CS
- Subjects
- Humans, Child, Male, Female, Child, Preschool, Infant, Adolescent, United States epidemiology, Tissue and Organ Procurement statistics & numerical data, Retrospective Studies, Waiting Lists mortality, Heart Transplantation mortality
- Abstract
Background: In 2016, the United Network for Organ Sharing revised its pediatric heart transplant (HT) allocation policy., Objectives: This study sought to determine whether the 2016 revisions are associated with reduced waitlist mortality and capture patient-specific risks., Methods: Children listed for HT from 1999 to 2023 were identified using Organ Procurement and Transplantation Network data and grouped into 3 eras (era 1: 1999-2006; era 2: 2006-2016; era 3: 2016-2023) based on when the United Network for Organ Sharing implemented allocation changes. Fine-Gray competing risks modeling was used to identify factors associated with death or delisting for deterioration. Fixed-effects analysis was used to determine whether allocation changes were associated with mortality., Results: Waitlist mortality declined 8 percentage points (PP) across eras (21%, 17%, and 13%, respectively; P < 0.01). At listing, era 3 children were less sick than era 1 children, with 6 PP less ECMO use (P < 0.01), 11 PP less ventilator use (P < 0.01), and 1 PP less dialysis use (P < 0.01). Ventricular assist device (VAD) use was 13 PP higher, and VAD mortality decreased 9 PP (P < 0.01). Non-White mortality declined 10 PP (P < 0.01). ABO-incompatible listings increased 27 PP, and blood group O infant mortality decreased 13 PP (P < 0.01). In multivariable analyses, the 2016 revisions were not associated with lower waitlist mortality, whereas VAD use (in era 3), ABO-incompatible transplant, improved patient selection, and narrowing racial disparities were. Match-run analyses demonstrated poor correlation between individual waitlist mortality risk and the match-run order., Conclusions: The 2016 allocation revisions were not independently associated with the decline in pediatric HT waitlist mortality. The 3-tier classification system fails to adequately capture patient-specific risks. A more flexible allocation system that accurately reflects patient-specific risks and considers transplant benefit is urgently needed., Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
20. Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation.
- Author
-
Scott FI, Ehrlich O, Wood D, Viator C, Rains C, DiMartino L, McArdle J, Adams G, Barkoff L, Caudle J, Cheng J, Kinnucan J, Persley K, Sariego J, Shah S, Heller C, and Rubin DT
- Subjects
- Humans, Referral and Consultation, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy, Gastroenterology
- Abstract
Background: Recommendations regarding signs and symptoms that should prompt referral of patients with inflammatory bowel disease (IBD) to an IBD specialist for a consultation could serve to improve the quality of care for these patients. Our aim was to develop a consult care pathway consisting of clinical features related to IBD that should prompt appropriate consultation., Methods: A scoping literature review was performed to identify clinical features that should prompt consultation with an IBD specialist. A panel of 11 experts was convened over 4 meetings to develop a consult care pathway using the RAND/UCLA Appropriateness Method. Items identified via scoping review were ranked and were divided into major and minor criteria. Additionally, a literature and panel review was conducted assessing potential barriers and facilitators to implementing the consult care pathway., Results: Of 43 features assessed, 13 were included in the care pathway as major criteria and 15 were included as minor criteria. Experts agreed that stratification into major criteria and minor criteria was appropriate and that 1 major or 2 or more minor criteria should be required to consider consultation. The greatest barrier to implementation was considered to be organizational resource allocation, while endorsements by national gastroenterology and general medicine societies were considered to be the strongest facilitator., Conclusions: This novel referral care pathway identifies key criteria that could be used to triage patients with IBD who would benefit from IBD specialist consultation. Future research will be required to validate these findings and assess the impact of implementing this pathway in routine IBD-related care., (© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2023
- Full Text
- View/download PDF
21. Increased risk of infections in pediatric Fontan patients after heart transplantation.
- Author
-
Ahmed H, Lee J, Bernstein D, Rosenthal D, Dykes J, Lee D, Barkoff L, Weinberg K, Hollander SA, and Chen S
- Subjects
- Humans, Child, Retrospective Studies, Cohort Studies, Incidence, Heart Transplantation adverse effects
- Abstract
Background: Infectious complications are a major cause of morbidity and mortality after HT. Fontan patients may be more susceptible to post-HT infections., Methods: This was a single-center, retrospective cohort analysis of pediatric patients undergoing HT for FF physiology or DCM, who underwent induction with ATG. The primary endpoint was an infection in the first 180 days post-HT, defined as positive (1) blood/urine/respiratory culture; (2) viral PCR; (3) skin or wound infection; and/or (4) culture-negative infection if ≥5 days of antibiotics were completed. Secondary endpoints included (1) cell counts after ATG; (2) PTLD; and (3) rejection (≥Grade 2R ACR or pAMR2) in the first 180 days post-HT., Results: A total of 59 patients (26 FF, 33 DCM) underwent HT at 14.7 (IQR 10.6, 19.5) and 11.7 (IQR 1.4, 13.6) years of age, respectively. The median total ATG received was 7.4 (IQR 4.9, 7.7) vs 7.5 (IQR 7.3, 7.6) mg/kg (p = NS) for FF and DCM patients, respectively. Twenty-three patients (39%) developed an infection 180 days post-HT, with a higher rate of infection in FF patients (54% vs 27%, p = .03). Adjusted for pre-transplant absolute lymphocyte count, FF patients had a higher risk of infection at 30 days post-HT (OR 7.62, 95% CI 1.13-51.48, p = .04). There was no difference in the incidence of PTLD (12% vs 0%; p = .08) or rejection (12% vs 21%; p = .49)., Conclusion: Compared to DCM patients, FF patients have a higher risk of infection. Modifications to induction therapy for FF patients should be considered., (© 2022 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
22. Risk factors and outcomes of sudden cardiac arrest in pediatric heart transplant recipients.
- Author
-
Hollander SA, Barkoff L, Giacone H, Adamson GT, Kaufman BD, Motonaga KS, Dubin AM, and Chubb H
- Subjects
- Child, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac etiology, Humans, Retrospective Studies, Risk Factors, Cardiopulmonary Resuscitation, Heart Arrest, Heart Transplantation
- Abstract
Background: Sudden cardiac arrest (SCA) is a prevailing cause of mortality after pediatric heart transplant (HT) but remains understudied. We analyzed the incidence, outcomes, and risk factors for SCA at our center., Methods: Retrospective review of all pediatric HT patients at our center from January 1, 2009 to January 1, 2021. SCA was defined as an abrupt loss of cardiac function requiring cardiopulmonary resuscitation and/or mechanical circulatory support (MCS). Events that occurred in the setting of limited resuscitative wishes, or while on MCS were excluded. Patient characteristics and risk factors were analyzed., Results: Fourteen of 254 (6%) experienced SCA at a median of 3 (1, 4) years post-HT. Seven (50%) events occurred out-of-hospital. Eleven (79%) died from their initial event, 2 (18%) after failure to separate from extracorporeal membrane (ECMO). In univariate analysis, black race, younger donor age, prior acute cellular rejection (ACR) episode, pacemaker and/or ICD in place, and pre-mortem diagnosis of allograft vasculopathy were associated with SCA (P = .003-0.02). In multivariable analysis, history of ACR, younger donor age, and black race retained significance. [OR = 6.3, 95% CI: 1.6-25.4, P = .01], [OR = 0.9, 95% CI: 0.8-1, P = .04], and [OR = 7.3, 95% CI: 1.1-49.9, P = .04], respectively. SCA occurred in 3 patients with a functioning ICD or pacemaker, which failed to restore a perfusing rhythm., Conclusions: SCA occurs relatively early after pediatric HT and is usually fatal. Half of events happen at home. Those who received younger donors, have a history of ACR, or are of black race are at increased risk. ICDs/pacemakers may offer limited protection., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
23. Healthy Hearts via Live Videoconferencing: An Exercise and Diet Intervention in Pediatric Heart Transplant Recipients.
- Author
-
Chen AC, Ramirez FD, Rosenthal DN, Couch SC, Berry S, Stauffer KJ, Brabender J, McDonald N, Lee D, Barkoff L, Nourse SE, Kazmucha J, Wang CJ, Olson I, and Selamet Tierney ES
- Subjects
- Adolescent, Age Factors, Child, Feasibility Studies, Female, Health Status, Heart Failure diagnosis, Heart Failure physiopathology, Heart Transplantation adverse effects, Humans, Male, Patient Compliance, Recovery of Function, Time Factors, Treatment Outcome, Young Adult, Diet, Healthy, Exercise, Heart Failure surgery, Heart Transplantation rehabilitation, Risk Reduction Behavior, Telerehabilitation, Videoconferencing
- Abstract
Background Pediatric heart transplant recipients have high-risk cardiovascular profiles that can affect their long-term outcomes; however, promoting exercise and healthy diet has not been a major focus in the field. The objective of this study was to test the feasibility and impact of a supervised exercise and diet intervention delivered via live videoconferencing in this population. Methods and Results Patients 8 to 19 years of age at least 1 year post heart transplantation were enrolled. The 12- to 16-week intervention phase included live video-supervised exercise (×3/week) and nutrition (×1/week) sessions. The 12- to 16-week maintenance phase included ×1/week live video-supervised exercise and nutrition sessions and ×2/week self-directed exercise sessions. Cardiac, vascular, nutritional, and functional health indices were obtained at baseline, after intervention, and after maintenance. Fourteen patients (median age, 15.2; interquartile range, 14.3-16.7 years) at a median of 3.3 (interquartile range, 1.5-9.7) years after heart transplant completed the intervention. Patients attended 89.6±11% of exercise and 88.4±10% of nutrition sessions during the intervention and 93.4±11% of exercise and 92.3±11% of nutrition sessions during maintenance. After intervention, body mass index percentile (median, -27%; P =0.02), endothelial function (median, +0.29; P =0.04), maximum oxygen consumption (median, +2 mL/kg per minute; P =0.002). Functional Movement Screening total score (median, +2.5; P =0.002) and daily consumption of saturated fat (median, -6 g; P =0.02) improved significantly. After maintenance, improvements in maximum oxygen consumption (median, +3.2 mL/kg per minute; P =0.02) and Functional Movement Screening total score (median, +5; P =0.002) were sustained. Conclusions In pediatric heart transplant recipients, a live video-supervised exercise and diet intervention is feasible. Our results demonstrate excellent adherence with significant improvements in cardiovascular and functional health. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02519946.
- Published
- 2020
- Full Text
- View/download PDF
24. Pediatric waitlist and heart transplant outcomes in patients with syndromic anomalies.
- Author
-
Wilkens SJ, Priest J, Kaufman BD, Barkoff L, Rosenthal DN, and Hollander SA
- Subjects
- Adolescent, Case-Control Studies, Child, Child, Preschool, Chromosome Disorders epidemiology, Connective Tissue Diseases epidemiology, Female, Heart Failure mortality, Humans, Infant, Infant, Newborn, Male, Mitochondrial Diseases epidemiology, Prevalence, Retrospective Studies, Survival Analysis, Syndrome, Chromosome Disorders complications, Connective Tissue Diseases complications, Heart Failure complications, Heart Failure surgery, Heart Transplantation, Mitochondrial Diseases complications, Waiting Lists mortality
- Abstract
Purpose: We sought to determine whether the presence of a systemic SA with potential complicating factors affects waitlist and post-HT outcomes in pediatric patients., Methods: This is a single-center retrospective review of pediatric patients listed for HT between January 1, 2009, and July 1, 2018. Patients were selected based on the presence of any underlying syndromes, which included chromosomal anomalies, skeletal myopathies, connective tissue disorders, mitochondrial disease,and other systemic disorders. Waitlist and post-HT outcomes were compared to those without SA., Results: A total of 243 patients were listed for HT, of which 21 (9%) patients had associated SA. Of those, 16 (76%) survived to transplant, 3 (14%) died while on the waitlist, 1 (5%) improved and was removed from the waitlist, and 1 (5%) patient is currently listed. Waitlist survival was not different between those with/without an associated syndrome (P = 1.0). Among those who survived to HT, there was no difference in listing days (70 vs 90, P = .8), survival to hospital discharge [14 (93%) vs 150 (95%), P = .6], post-HT intubation days (2 vs 2 days, P = .6), or post-HT hospital length of stay (18 vs 18 days, P = .8). Overall survival during the study period post-HT was not different between groups (P = .8)., Conclusion: A SA was present in 9% of pediatric patients wait-listed for HT, but was not associated with an increased waitlist mortality or post-HT hospital morbidity or long-term survival. For several anomalies, HT is safe and feasible., (2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
25. Healthy hearts in pediatric heart transplant patients with an exercise and diet intervention via live video conferencing-Design and rationale.
- Author
-
Chen AC, Rosenthal DN, Couch SC, Berry S, Stauffer KJ, Brabender J, McDonald N, Lee D, Barkoff L, Nourse SE, Kazmucha J, Wang CJ, Olson I, and Selamet Tierney ES
- Subjects
- Adolescent, Cardiovascular Diseases etiology, Child, Feasibility Studies, Female, Health Behavior, Health Promotion methods, Healthy Lifestyle, Humans, Male, Patient Compliance statistics & numerical data, Research Design, Treatment Outcome, Young Adult, Cardiovascular Diseases prevention & control, Diet Therapy methods, Exercise Therapy methods, Heart Transplantation, Postoperative Complications prevention & control, Telemedicine methods, Videoconferencing
- Abstract
Background: Pediatric heart transplant (PedHtx) patients have increased cardiovascular risk profiles that affect their long-term outcomes and quality of life. We designed a 12- to 16-week diet and exercise intervention delivered via live video conferencing to improve cardiovascular health. Our methodology and baseline assessment of the first 13 enrolled patients are reported., Methods: Inclusion criteria are as follows: (a) 8-19 years old; (b) heart transplant >12 months; (c) ability to fast overnight; (d) cardiac clearance by cardiologist; and (e) presence of an adult at home during exercise sessions for patients <14 years old. Exclusion criteria are as follows: (a) acute illness; (b) latex allergy; (c) transplant rejection <3 months ago; and (d) multi-organ transplantation. The intervention consists of one diet and three exercise sessions weekly via live video conferencing. Study visits are conducted at baseline, intervention completion, and end of maintenance period., Results: A total of 13 participants (15.2 [2.3] years) have been enrolled. Median percent-predicted VO
2 max was 56.8 [20.7]% (10 patients <70%). Ten patients had abnormal endothelial function (reactive hyperemia index <1.9; 1.4 [0.325]) and 11 patients had stiff arteries (pulse wave velocity ≧5.5 m/s for 15-19 years, ≧4.5 m/s for 8-14 years; 5.6 [0.7] m/s). Patients had suboptimal diets (saturated fat: 22.7 [23.8] g/d, sodium: 2771 [1557] mg/d) and were sedentary at a median of 67.5 [13.8]% of their time., Conclusions: Baseline assessment confirms that PedHtx patients have abnormal cardiac, vascular, and functional health indices, poor dietary habits, and are sedentary. These results support the rationale to test the feasibility and impact of a non-pharmacologic lifestyle intervention in this patient population., (© 2018 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
26. The End-of-Life Experience of Pediatric Heart Transplant Recipients.
- Author
-
Hollander SA, Dykes JC, Chen S, Barkoff L, Sourkes B, Cohen H, Rosenthal DN, Bernstein D, and Kaufman BD
- Subjects
- California epidemiology, Child, Child, Preschool, Female, Humans, Infant, Male, Palliative Care statistics & numerical data, Prevalence, Retrospective Studies, Risk Factors, Survival Rate, Heart Failure mortality, Heart Failure therapy, Heart Transplantation mortality, Hospitalization statistics & numerical data, Intensive Care Units statistics & numerical data, Terminal Care statistics & numerical data
- Abstract
Context: Despite advances in therapies, many pediatric heart transplant (Htx) recipients will die prematurely. We characterized the circumstances surrounding death in this cohort, including location of death and interventions performed in the final 24 hours., Methods: We reviewed all patients who underwent Htx at Lucile Packard Children's Hospital, Stanford, survived hospital discharge, and subsequently died between July 19, 2007 and September 13, 2015. The primary outcome studied was location of death, characterized as inpatient, outpatient, or emergency department. Circumstances of death (withdrawal of life-sustaining treatment, death during resuscitation, or death without resuscitation with/without do not resuscitate) and interventions performed in the last 24 hours of life were also analyzed., Results: Twenty-three patients met the entry criteria. The median age at death was 12 (range 2-20) years, and the median time between transplant and death was 2.8 (range 0.8-11) years. Four (17%) died at home, and three (13%) died in the emergency department. Sixteen (70%) patients died in the hospital, 14 of 16 (88%) of whom died in an intensive care unit. Five of 23 (22%) patients experienced attempted resuscitation. Interventions performed in the last 24 hours of life included intubation (74%), mechanical support (30%), and dialysis (22%). Most patients had a recent outpatient clinical encounter with normal graft function within 60 days of dying., Conclusions/lessons Learned: Death in children after Htx often occurs in the inpatient setting, particularly the intensive care unit. Medical interventions, including attempted resuscitation, are common at the end of life. Given the difficulty in anticipating life-threatening events, earlier discussions with patients regarding end-of-life wishes are appropriate, even in those with normal graft function., (Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
27. A cross-sectional study of barriers to personal health record use among patients attending a safety-net clinic.
- Author
-
Hilton JF, Barkoff L, Chang O, Halperin L, Ratanawongsa N, Sarkar U, Leykin Y, Muñoz RF, Thom DH, and Kahn JS
- Subjects
- Consumer Health Information statistics & numerical data, Cross-Sectional Studies, Female, Health Surveys, Humans, Male, Mental Health Services statistics & numerical data, Middle Aged, Health Records, Personal psychology, Internet statistics & numerical data, Mental Disorders psychology, Substance-Related Disorders psychology
- Abstract
Background: Personal health records (PHR) may improve patients' health by providing access to and context for health information. Among patients receiving care at a safety-net HIV/AIDS clinic, we examined the hypothesis that a mental health (MH) or substance use (SU) condition represents a barrier to engagement with web-based health information, as measured by consent to participate in a trial that provided access to personal (PHR) or general (non-PHR) health information portals and by completion of baseline study surveys posted there., Methods: Participants were individually trained to access and navigate individualized online accounts and to complete study surveys. In response to need, during accrual months 4 to 12 we enhanced participant training to encourage survey completion with the help of staff. Using logistic regression models, we estimated odds ratios for study participation and for survey completion by combined MH/SU status, adjusted for levels of computer competency, on-study training, and demographics., Results: Among 2,871 clinic patients, 70% had MH/SU conditions, with depression (38%) and methamphetamine use (17%) most commonly documented. Middle-aged patients and those with a MH/SU condition were over-represented among study participants (N = 338). Survey completion was statistically independent of MH/SU status (OR, 1.85 [95% CI, 0.93-3.66]) but tended to be higher among those with MH/SU conditions. Completion rates were low among beginner computer users, regardless of training level (<50%), but adequate among advanced users (>70%)., Conclusions: Among patients attending a safety-net clinic, MH/SU conditions were not barriers to engagement with web-based health information. Instead, level of computer competency was useful for identifying individuals requiring substantial computer training in order to fully participate in the study. Intensive on-study training was insufficient to enable beginner computer users to complete study surveys.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.